SEARCH:
Print

Clinical Trials

Bavarian Nordic and its partners conduct clinical studies of its vaccine candidates to evaluate their safety and efficacy.

Clinical studies that are actively enrolling patients or are planned are detailed below.

Cancer immunotherapy product candidates

PRODUCT DETAILS LOCATION LINKS
PROSTVAC Phase 1/2 Study of PROSTVAC in Combination With Nivolumab and / or Ipilimumab in Men With Prostate Cancer USA NCT02933255
PROSTVAC Phase 2 Trial of PROSTVAC and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy USA NCT02506114
PROSTVAC Phase 2 Randomized, Placebo-Controlled Trial of PROSTVAC in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance USA NCT02326805
PROSTVAC Phase 2 Study of Neoadjuvant PROSTVAC in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy USA NCT02153918
PROSTVAC Phase 2 Trial of Adjuvant PROSTVAC in Subjects at High Risk for Relapse After Radical Prostatectomy USA NCT02772562
PROSTVAC Phase 2 Study of PROSTVAC in Patients With Biochemical Recurrent Prostate Cancer USA NCT02649439
PROSTVAC Phase 2 Study of PROSTVAC and Docetaxel for Metastatic Castration Sensitive Prostate Cancer USA NCT02649855
PROSTVAC Phase 2 Study Combining PROSTVAC with Enzalutamide vs. Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer USA NCT01867333
CV301 Phase 1/2 Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer USA NCT02840994
CV301 Phase 2 Study Combining CV301 (PANVAC) with Bacillus Calmette-Guerin (BCG) vs. BCG Alone in High Grade Non-Muscle Invasive Bladder Cancer USA NCT02015104

Infectious disease product candidates

PRODUCT DETAILS LOCATION LINKS
IMVAMUNE Phase 3 study, designed to demonstrate non-inferiority between IMVAMUNE and the current U.S. licensed smallpox vaccine (ACAM2000®) South Korea (US) NCT01913353
MVA-BN Filo Phase 1 dose-escalating study evaluating the safety, tolerability, and immunogenicity of cAd3-EBO Z and MVA-BN Filo in healthy adult participants. United Kingdom NCT02240875
MVA-BN Filo Phase 2 study evaluating the safety, tolerability and immunogenicity of MVA-BN Filo and Ad26.ZEBOV administered in different sequences and schedules in healthy adult participants. United Kingdom/
France
NCT02416453
MVA-BN Filo Phase 2 study evaluating the safety, tolerability and immunogenicity of three prime-boost regimens of MVA-BN Filo and Ad26.ZEBOV in healthy adult participants, including elderly, HIV-infected, and healthy children in three age strata. Uganda/
Kenya
NCT02564523
MVA-BN Filo Phase 3 study evaluating the safety and immunogenicity of Ebola candidate vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone) Sierra Leone NCT02509494
MVA-BN Filo Phase 3 Study to Evaluate A Range of Dose Levels of a Heterologous Prime‐Boost Regimen of Ad26.ZEBOV and MVA‐BN®‐Filo in Healthy Adult Subjects USA NCT02543567
MVA-BN YF Phase 1 Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers USA NCT02743455
MVA-BN RSV Phase 2 Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine USA NCT02873286
MVA-BN RSV Phase 1 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA-BN® RSV Vaccine After Intranasal and Intramuscular Administration USA NCT02864628